TD Asset Management Inc. decreased its position in shares of AveXis, Inc. (NASDAQ:AVXS) by 32.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,247 shares of the company’s stock after selling 7,000 shares during the period. TD Asset Management Inc.’s holdings in AveXis were worth $1,378,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently bought and sold shares of the business. FMR LLC increased its position in AveXis by 13.1% during the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after acquiring an additional 544,475 shares during the last quarter. BlackRock Inc. grew its holdings in shares of AveXis by 34.7% in the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock worth $189,069,000 after purchasing an additional 592,843 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of AveXis by 31.8% in the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock worth $129,419,000 after purchasing an additional 380,396 shares during the last quarter. State Street Corp grew its holdings in shares of AveXis by 104.2% in the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after purchasing an additional 510,189 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of AveXis in the second quarter worth about $55,439,000. Institutional investors and hedge funds own 92.88% of the company’s stock.
A number of research firms have recently commented on AVXS. Zacks Investment Research cut shares of AveXis from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Chardan Capital restated a “buy” rating on shares of AveXis in a report on Thursday, November 2nd. Royal Bank of Canada restated a “hold” rating and issued a $92.00 price target on shares of AveXis in a report on Thursday, November 2nd. Jefferies Group upped their price target on shares of AveXis to $118.00 and gave the stock a “buy” rating in a report on Thursday, October 12th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $130.00 price target (up from $123.00) on shares of AveXis in a report on Thursday, October 12th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $110.67.
In related news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $101.46, for a total value of $1,521,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at $180,242.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,340 shares of company stock valued at $5,172,298. 18.60% of the stock is owned by insiders.
Shares of AveXis, Inc. (NASDAQ AVXS) opened at $98.09 on Tuesday. AveXis, Inc. has a one year low of $44.68 and a one year high of $108.27.
AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the firm earned ($0.87) EPS. analysts anticipate that AveXis, Inc. will post -6.23 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “TD Asset Management Inc. Has $1.38 Million Holdings in AveXis, Inc. (AVXS)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/12/td-asset-management-inc-has-1-38-million-holdings-in-avexis-inc-avxs.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.